Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8657243 | 0.97 | — | — | |
| SCHEMBL5031088 | 0.85 | CA1 (0.35) | CA1CA2CA12CA9NPC1 | |
| SCHEMBL5554325 | 0.82 | CA1 (0.33) | CA1CA2CA12CA9NPC1 | |
| SCHEMBL5027508 | 0.78 | ACHE (0.31) | CA1CA2CA12CA9 | |
| SCHEMBL5029872 | 0.78 | ACHE (0.31) | CA1CA2CA12CA9 | |
| SCHEMBL5032364 | 0.78 | ACHE (0.31) | CA1CA2CA12CA9 | |
| SCHEMBL5029784 | 0.76 | ACHE (0.30) | CA1CA2 | |
| SCHEMBL5029807 | 0.76 | ACHE (0.30) | CA1CA2 | |
| SCHEMBL19952926 | 0.75 | CA1 (0.36) | CA1CA2CA12CA9NPC1 | |
| SCHEMBL1322990 | 0.75 | CA1 (0.36) | CA1CA2CA12CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106543316-A | For the catalytic component of olefinic polymerization, catalyst and preparation method thereof | 中国石油化工股份有限公司 | 2017-03-29 | — | — | CN | claimed |
| CN-108026205-A | The manufacture method and its rubber composition of silica mixing modified solution polymerization polydiene | 有限会社ＥＴＩＣ | 2018-05-11 | — | — | CN | disclosed |
| CN-106543316-A | For the catalytic component of olefinic polymerization, catalyst and preparation method thereof | 中国石油化工股份有限公司 | 2017-03-29 | — | — | CN | disclosed |
| CN-101472959-A | Ziegler-Natta catalyst with in situ-generated donor | NOVOLEN TECH HOLDINGS CV (NL) | 2009-07-01 | — | — | CN | disclosed |
| EP-1999167-A2 | ZIEGLER-NATTA CATALYST WITH IN SITU-GENERATED DONOR | Novolen Technology Holdings, C.V. (NL) | 2008-12-10 | — | — | EP | disclosed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2007106348-A2 | ZIEGLER-NATTA CATALYST WITH IN SITU-GENERATED DONOR | NOVOLEN TECHNOLOGY HOLDINGS C.V. (NL) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213204-A1 | Ziegler-Natta catalyst with in situ-generated donor | NOVOLEN TECHNOLOGY HOLDINGS C.V. | 2007-09-13 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| US-5122490-A | Composed of organomagesium compounds, titanium and vanadium halides, alcohols, halogenated silanes, siloxanes, borates, electron donors and cyclic ether | CHISSO CORPORATION (JP) | 1992-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | CA1 3767/4885CA2 2818/4885CA12 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.